Prostate Biopsy News and Research

RSS

The prostate is a small gland that wraps around the urethra, at the base of the urinary bladder. It produces semen, the fluid vehicle of spermatozoa. A biopsy of the prostate is a procedure in which a small sample of prostate tissue is removed in order to examine it, usually in search for signs of malignant transformation of prostate cells.

Precision-medicine approach could improve accuracy of PSA-based prostate cancer screening tests

A new study led by researchers at UC San Francisco and Kaiser Permanente has identified genetic predictors of normal prostate-specific antigen (PSA) levels in healthy men, which could be used to improve the accuracy of PSA-based prostate cancer screening tests.

3 Feb 2017

Lancet study: Advanced MRI doubles detection of aggressive tumours

A study published in The Lancet on 19th January 2017 entitled ‘Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study’ shows that using advanced MRI almost doubles the number of aggressive tumours detected.

27 Jan 2017

A quarter of men could safely avoid prostate biopsy if MRI is used

Performing an MRI scan of men with suspected prostate cancer could spare a quarter of men from having to undergo prostate biopsy, according to a study published in The Lancet.

20 Jan 2017

PITX2 methylation biomarker shows promise for predicting prostate cancer recurrence risk

Prostate-specific antigen (PSA) and other biomarkers are essential tools for diagnosing and monitoring prostate cancer.

8 Dec 2016

Risk and reality do not always match up in prostate cancer biopsies, research suggests

When it comes to prostate cancer biopsies, risk and reality don't always match up, according to research published online today in the Journal of Clinical Oncology.

1 Nov 2016

Intermediate risk prostate cancer patients can achieve survival benefit with brachytherapy alone

For men with intermediate risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects, when compared to more aggressive treatment that combines brachytherapy with external beam therapy (EBT), according to research presented today at the 58th Annual Meeting the American Society for Radiation Oncology.

27 Sep 2016

Innovative procedure combining MRI and ultrasound can accurately diagnose prostate cancer

New research confirms that an innovative procedure combining MRI and ultrasound to create a 3D image of the prostate can more accurately locate suspicious areas and help diagnose whether it's prostate cancer.

14 Sep 2016

Screening PSA levels in younger men could accurately predict future risk of prostate cancer

Prostate cancer screening with prostate-specific antigen (PSA) has been shown to reduce death and the spread of prostate cancer to other parts of the body, but the PSA test remains highly controversial as it frequently leads to over diagnosis and over treatment of men who may not be at risk.

14 Jun 2016

RSI-MRI imaging technology can effectively differentiate aggressive prostate cancer

Physicians have long used magnetic resonance imaging (MRI) to detect cancer but results of a University of California San Diego School of Medicine study describe the potential use of restriction spectrum imaging (RSI) as an imaging biomarker that enhances the ability of MRI to differentiate aggressive prostate cancer from low-grade or benign tumors and guide treatment and biopsy.

2 Jun 2016

Axumin approved for use in PET scans in patients with recurrent prostate cancer

The U.S. Food and Drug Administration today approved Axumin, a radioactive diagnostic agent for injection. Axumin is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated prostate specific antigen (PSA) levels following prior treatment.

28 May 2016

New IsoPSA test identifies molecular structural changes in protein biomarkers to detect prostate cancer

A promising new test is detecting prostate cancer more precisely than current tests, by identifying molecular changes in the prostate specific antigen (PSA) protein, according to Cleveland Clinic research presented today at the American Urological Association annual meeting.

12 May 2016

Experimental urine test identifies 92% of men with elevated PSA levels

An experimental urine test that detects genetic changes associated with prostate cancer identified 92 percent of men with elevated PSA (prostate-specific antigen) levels who had high-grade cancers, according to a study published today in JAMA Oncology online.

1 Apr 2016

ANGLE’s Parsortix system may be used for detection of prostate cancer, Barts patient data suggests

ANGLE plc, the specialist medtech company, is delighted to announce that the results of Barts Cancer Institute’s ongoing work with ANGLE’s Parsortix system have provided evidence in support of the use of Parsortix in the detection and assessment of prostate cancer.

22 Mar 2016

Newly identified RNA biomarkers open door for simple, accurate non-invasive test for prostate cancer

A study on non-coding RNA (Ribonucleic Acid) from prostate cancer patients has identified a series of new prostate cancer markers which can be found in urine. Combining these RNA markers into a single test potentially opens the door for simple, accurate non-invasive testing for prostate cancer.

14 Mar 2016

Active surveillance recommended for low-risk prostate cancer

For most men with low-risk prostate cancer, the recommended strategy is active surveillance with regular testing to check for cancer growth rather than immediate treatment, according to guidelines from the American Society of Clinical Oncology.

18 Feb 2016

Liverpool researchers reach major milestone towards creating diagnostic test for prostate cancer

A research team from the University of Liverpool has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.

12 Feb 2016

VolitionRx initiates study to assess NuQ blood tests for detection of prostate cancer

VolitionRx Limited today announced that it has initiated a study to assess the feasibility of using the Company’s NuQ blood tests to detect prostate cancer. The study is in collaboration with the Surrey Cancer Research Institute of the University of Surrey in the UK.

5 Feb 2016

MDxHealth recognized with 2015 Global Frost & Sullivan Award for Technology Innovation

Based on its recent analysis of the prostate cancer diagnostics market, Frost & Sullivan recognizes MDxHealth with the 2015 Global Frost & Sullivan Award for Technology Innovation. To advance molecular diagnostic tests for urological cancers, MDxHealth supplemented its prostate cancer test, ConfirmMDx, with a urine-based "liquid-biopsy" test called SelectMDx.

21 Jan 2016

African American men with prostate cancer have significantly lower PSA density than Caucasian men

A new study published in The Journal of Urology revealed that African American men with Gleason score 3+3=6 prostate cancer (PCa) produce less prostate specific antigen (PSA) and have significantly lower PSA density (PSAD) than Caucasian men. These findings could have important implications when selecting patients for inclusion in active PCa surveillance programs.

5 Jan 2016

Repeating abnormal PSA tests can reduce unnecessary biopsies

For more than 20 years, the prostate-specific antigen (PSA) test has been used to help screen for prostate cancer, but in recent years, some task forces have called for this blood test to be abandoned because it leads to many unnecessary biopsies.

11 Dec 2015